- Home
- NXP vs OPK Comparison
NXP vs OPK Comparison
Compare NXP & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NXP | OPK |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 1.0B |
| IPO Year | 1995 | 2011 |
Fundamental Metrics
Financial Performance| Metric | NXP | OPK |
|---|---|---|
| Price | $14.17 | $1.68 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.60 |
| AVG Volume (30 Days) | 141.1K | ★ 2.7M |
| Earning Date | 01-01-0001 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.89 | $0.98 |
| 52 Week High | $14.65 | $1.73 |
Technical Indicators
Market Signals| Indicator | NXP | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 44.70 | 72.89 |
| Support Level | $14.05 | $1.12 |
| Resistance Level | $14.49 | $1.73 |
| Average True Range (ATR) | 0.07 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 32.56 | 89.02 |
Price Performance
Historical ComparisonAbout NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund has single operating segment.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.